The present study was designed to determine whether ADT modulates TMPRSS2 expression in the lung tissue of prostate cancer patients and to assess whether specific ADT regimens differ in their effects on pulmonary TMPRSS2 levels. This evidence concerns the gene TMPRSS2 and prostate carcinoma.